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ABSTRACT: A large number of clinically used drugs and
experimental pharmaceuticals possess the N,N-dimethyltrypt-
amine (DMT) structural core. Previous reports have described
the reaction of this motif with dichloromethane (DCM), a
common laboratory solvent used during extraction and
purification, leading to the formation of an undesired
quaternary ammonium salt byproduct. However, the kinetics
of this reaction under various conditions have not been
thoroughly described. Here, we report a series of experiments
designed to simulate the exposure of DMT to DCM that
would take place during extraction from plant material,
biphasic aqueous work-up, or column chromatography
purification. We find that the quaternary ammonium salt
byproduct forms at an exceedingly slow rate, only accumulates to a significant extent upon prolonged exposure of DMT to DCM,
and is readily extracted into water. Our results suggest that DMT can be exposed to DCM under conditions where contact times
are limited (<30 min) with minimal risk of degradation and that this byproduct is not observed following aqueous extraction.
However, alternative solvents should be considered when the experimental conditions require longer contact times. Our work has
important implications for preparing a wide-range of pharmaceuticals bearing the DMT structural motif in high yields and
purities.
1. INTRODUCTION
A wide-variety of bioactive compounds contain the N,N-
dimethyltryptamine (DMT) structural motif (Figure 1). The
parent compound DMT (1) is the primary hallucinogenic
component of ayahuascaan Amazonian tisane used in
traditional medicine and for religious purposes.1 There is a
growing interest in the therapeutic potential of DMT because
of recent clinical data demonstrating that ayahuasca produces
rapid antidepressant effects in humans that resemble those of
the prototypical fast-acting antidepressant ketamine.2−5 Fur-
thermore, DMT is capable of producing behavioral effects in
rodents relevant to the treatment of depression and post-
traumatic stress disorder.6 Other psychedelics possessing the
DMT structural core, such as psilocybin (2) and ibogaine (3),
have also demonstrated therapeutic potential for treating
various neuropsychiatric disorders including depression,
anxiety, and addiction.7,8 Taken together, these data suggest
that psychedelics possessing the DMT core structure may have
value as medicines and cannot simply be labeled as drugs of
abuse.9
In addition to the classical serotonergic psychedelics, a
variety of other bioactive compounds contain the DMT
structural motif. These include the triptan drugs sumatriptan
(4), zolmitriptan (5), and rizatriptan (6) (Figure 1)
compounds that are widely prescribed for treating migraines
and cluster headaches as well as the 5-HT6 ligands EMDT (7),
MS-245 (8), and ST1936 (9).10 The latter compounds are still
in the experimental phase but have shown great promise in
preclinical models and in clinical trials for improving cognitive
deficits associated with Alzheimer’s disease and depression.11
Because of the ubiquity of the DMT structural motif in
molecules of medicinal importance, it is imperative to identify
methods for their preparation and purification that maximize
yield and purity while minimizing cost.
During the course of our studies regarding the synthesis and
biological evaluation of DMT derivatives, we became aware of
reports detailing the reaction of DMT with dichloromethane
(DCM) to form N-chloromethyl-N,N-dimethyltryptamine
chloride 10 (Scheme 1).12−14 These findings have caused
some chemists to question the appropriateness of using DCM
in the synthesis, work-up, or purification of DMT derivatives,
despite the fact that DCM possesses many desirable traits like
being one of the only commercially available low boiling
solvents that is nonflammable.15 One common alternative to
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DCM is diethyl ether, but the latter can be quite hazardous due
to its low flash point (−45 °C), low autoignition temperature
(180 °C), and ability to form peroxides.16 Chloroform is
another solvent commonly used as a replacement for DCM, but
it is far from perfect. In the presence of a base, it can form
dichlorocarbene, which is known to react with indoles and
amines.17 Additionally, it causes a variety of adverse health
effects that are less likely to be caused by DCM.18,19 Finally,
both diethyl ether and chloroform are significantly more
expensive than DCM (circa 1.5×). Therefore, despite the
possibility of amines reacting with DCM through an SN2
reaction, this solvent remains attractive from safety and
economic standpoints.19
While there have been several studies reporting the reactivity
of DCM with amines, such reactions are highly substrate
dependent.20,21 Tertiary amines appear to be the most
susceptible to reactions with DCM, though the reactivity of
secondary amines has also been reported.20 Secondary amines
stored in DCM transiently form an N-chloromethyl product
that establishes a rapid equilibrium with the iminium chloride.
In the presence of excess amine, the major product formed is
the symmetrical aminal.20 As the half-life of triethylamine in
DCM is on the order of hours to days,21 we hypothesized that
the reaction of DMT with DCM might be negligible under
typical conditions used to either extract the natural product
from plant sources or produce it synthetically. Here, we confirm
that DMT does form 10 when stored in DCM for extended
periods of time as previously reported.12−14 However, we find
that under typical experimental conditions, the reaction of
DMT with DCM does not negatively impact the reaction yield
or increase the risk of contamination by 10. We conclude that
DCM is a suitable solvent for the work-up and purification of
DMT and related analogs and that 10 is unlikely to be useful as
a diagnostic impurity characterizing batches of DMT produced
by specific clandestine laboratories, as previously suggested.14
2. RESULTS AND DISCUSSION
2.1. Synthesis of Analytical Standards. First, we
prepared pure DMT and 10 as described previously for use
as analytical standards.6,13,14 For reference, the 1H NMR and
LC−MS (liquid chromatography−mass spectrometry) spectra
are presented in Figure 2. Characterization data for 1 and 10
were consistent with previous reports.6,12
2.2. DMT Degradation in Pure Solvent. Alkaloids are
commonly extracted from plant material using DCM.22 To
mimic such conditions, we dissolved a DMT free base in DCM
and observed the formation of 10 via 1H NMR as a function of
time.23 While previous reports have described the formation of
10 after extended reaction times, the rate of its formation was
previously unknown.13,14 By comparing the integrations of the
peaks corresponding to DMT (1) with those corresponding to
10, we could determine the rate of the reaction. In a pure
solvent, the reaction of 1 with DCM is quite clean yielding 10
as the only observable product by 1H NMR (Figure 3A) or
LC−MS (data not shown). After 1 h, the percentage of 10 in
the mixture was 0.8%, and it reached 38% after 4 days (Figure
3B). Crystals of 10 were observed to precipitate around day 2
when the starting concentration of DMT was 10 mg/mL. The
pseudo-first-order rate constant k1 for this reaction was
calculated to be 1.21 × 10−5 s−1 and is comparable to that
previously reported for the reaction of DCM with trimethyl-
amine.21 Like trimethylamine, DMT reacts approximately 35×
faster with DCM than triethylamine, but only 2× as fast as the
secondary amine piperidine.21 Compared with the bulkier
tertiary amine N-methylpiperidine, DMT reacts nearly 10× as
fast highlighting the importance of steric effects in the reaction
of amines with DCM.21 Though DMT and trimethylamine
react faster with DCM than most amines (with the exception of
quinuclidine), this reaction is still quite slow when compared
with their reaction with methyl iodide. For example, trimethyl-
amine reacts with methyl iodide approximately 3000× faster
than it does with DCM.21,23 Notably, when chloroform was
used as the solvent, no appreciable decomposition of DMT (1)
was observed (data not shown). When the reaction between
DMT and DCM was carried out at −20 °C, the amount of 10
formed was less than 1% as determined by NMR after 4 days.
While the rate of formation of 10 is quite slow in DCM, care
should be taken when lengthy extraction protocols are required.
In such cases, chloroform may be a more appropriate solvent
choice.
2.3. DMT Degradation under Biphasic Basic Work-Up
Conditions. While the rate of formation of 10 in DCM is
relatively slow, appreciable amounts were observed after several
days. However, it is quite uncommon for reactive tertiary
amines to be left in solvent for multiple days at a time.
Therefore, we were interested in assessing the formation of 10
under more typical experimental conditions, namely, those
corresponding to a biphasic aqueous work-up. Because of the
partitioning between the organic and aqueous phases, one
might expect to form 10 at an accelerated rate because of the
dynamic removal of the ammonium salt product from the
organic layer where the SN2 reaction occurs. In fact, Brandt and
co-workers have reported that a basic aqueous work-up using
DCM following the synthesis of DMT (1) resulted in the
formation of 10, which constituted 4% of the total peak area in
the LC-UV trace.13 As Brandt and co-workers did not precisely
Figure 1. Chemical structures of DMT and related compounds. The
DMT structural motif is found in a variety of bioactive natural
products, known drugs, and experimental therapeutics.
Scheme 1. Reaction of DMT with DCMa
aDMT reacts with DCM via an SN2 reaction to produce N-
chloromethyl-N,N-dimethyltryptamine chloride 10.
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quantify the formation of 10, we subjected DMT to DCM/
NaOHaq biphasic work-up conditions and monitored the
formation of 10 in both layers as a function of time using
LC−MS with selective ion monitoring (SIM). In our hands, we
observed that the rate of DMT degradation under biphasic
conditions is comparable to that in pure DCM (Figure 4A,B).
By 24 h, 5% of 10 was observed in the aqueous layer,
comparable to the 4% observed in pure DCM conditions.
Importantly, we discovered that 10, likely because of its ionic
nature, partitions almost exclusively into the aqueous phase,
resulting in undetectable amounts of 10 contaminating the
DMT dissolved in the organic phase (Figure 4B).
Because of fear of forming impurity 10, others have preferred
the use of chloroform to DCM for extracting DMT free base.
However, chloroform is known to form dichlorocarbene under
basic conditions, such as those employed in aqueous work-ups
involving amines.17 Therefore, we wished to directly compare
the yields and purities of synthetic DMT subjected to basic
biphasic work-up conditions utilizing either DCM, chloroform,
or diethyl ether. The work-ups were carefully timed such that
the solvent was completely removed 30 min following the
initial exposure of DMT to solvent. Inspection of the unpurified
1H NMRs revealed that 10 was unobservable following aqueous
Figure 2. Characterization data for purified DMT/fumarate (2:1) and 10. 1H NMR spectra taken in DMSO-d6 for DMT (A) and 10 (B). Insets
depict LC−MS traces and mass spectra for each compound.
Figure 3. Formation of 10 in pure solvent. (A) Reaction of DMT (1)
with DCM to produce 10 monitored by 1H NMR over time. The
peaks highlighted in gray were used to quantify the molar ratio of 1 to
10. (B) Quantification of the peaks in A demonstrates that 10 reaches
38 mol % after 4 days.
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work-up regardless of the organic solvent employed (Figure
4C). This fact makes it unlikely that 10 can be used as a
diagnostic impurity when trying to identify DMT produced by
clandestine laboratories using DCM in their syntheses. After
crystallization as the fumarate salt, the synthetic DMT
produced using these three distinct work-up conditions was
judged to be analytically pure (via 1H NMR, and LC−MS).
Furthermore, the yields of the final product were comparable
(79−86%), regardless of the solvent used during the work-up.
Thus, we conclude that DCM/NaOHaq is a perfectly suitable
extraction system for the work-up of synthetically produced
DMT, as long as the contact times are minimized (<30 min).
2.4. DMT Degradation Following Purification via
Chromatography. Basic amines such as DMT (1) are often
purified via flash chromatography with the most common
solvent system being 9:1 DCM/MeOH with 1% NH4OHaq. In
fact, similar conditions produced 10 from an extract of Acacia
confusa, and the authors concluded that its formation was an
artifact of the isolation conditions.12 Following chromatography
using this solvent system, amines are often left to sit in the
collected fractions for a period of time, and thus, we were
interested to measure the conversion of DMT to 10 in 9:1
DCM/MeOH with 1% NH4OHaq (Figure 5A,B). After 1 h, the
percentage of 10 in the mixture was 2% and had reached 6% by
24 h, comparable to previously seen quantities at 24 h. The
reaction proceeded under pseudo-first-order conditions at a
comparable rate to that of DMT in pure DCM, and thus, it
would appear that the addition of MeOH and NH4OHaq has
very little effect on the rate of the reaction of DMT with DCM.
However, we recommend that fractions containing DMT be
concentrated within 1 h or stored at −20 °C following column
chromatography using 9:1 DCM/MeOH with 1% NH4OHaq as
the solvent system to minimize any potential for degradation.
3. CONCLUSIONS
Here, we have demonstrated that 1 will form 10 in the presence
of DCM as described previously.12−14 However, the rate of this
reaction is exceedingly slow under most common experimental
conditions, and significant amounts of this impurity do not
accumulate when contact times are limited (<30 min) or when
cryogenic temperatures are used. Therefore, concerns regarding
the use of DCM during the preparation of DMT (and likely
other related dimethyltryptamine analogs) are not warranted. It
has been previously suggested that forensic teams could use 10
as a diagnostic impurity to identify clandestine laboratories
using DCM in their syntheses of DMT. However, we think that
this possibility is unlikely due to the readily extractable nature
Figure 4. Formation of 10 under basic biphasic work-up conditions. (A) Formation of 10 in the aqueous phase as a function of time. Quantification
was achieved by determining relative peak ratios of 10 and an internal standard (caffeine) and comparing those values to a calibration curve. (B)
Combined LC−MS traces using SIM (masses = 189, DMT; 237, 10; 195, caffeine) of the aqueous and organic phases after 24 h of biphasic work-up
conditions. The presence of 10 was only detected in the aqueous layer. (C) Unpurified 1H NMRs taken in CDCl3 following the synthesis and 30 min
biphasic basic aqueous work-up of DMT (1) using three different solvents. Comparable purity of DMT was obtained, regardless of the solvent used
during the work-up. Isolated yields following crystallization as the fumarate salt (2:1 DMT/fumarate) are indicated.
Figure 5. Formation of 10 under purification conditions. (A) Reaction
of DMT (1) with 9:1 DCM/MeOH with 1% NH4OHaq to produce 10
monitored by 1H NMR over time. The peaks highlighted in gray were
used to quantify the molar ratio of 1 to 10. (B) Quantification of the
peaks in A demonstrates that 10 reaches 6 mol % after 24 h.
ACS Omega Article
DOI: 10.1021/acsomega.8b00507
ACS Omega 2018, 3, 4968−4973
4971
of 10 in water as well as the slow rate of reaction between 1 and
DCM. Although there are still environmental concerns with
using chlorinated solvents such as DCM, this study has shown
that its use has no effect on the purity or yield of the final DMT
product as compared to other common laboratory solvents.
Dimethyltryptamine and related analogs have high medicinal
value, and our work answers some fundamental questions
regarding their economical preparation in excellent yields and
purities.
4. METHODS
4.1. Materials. The DCM (ACS reagent grade, stabilized),
chloroform (HPLC grade), and all other reagents used in these
studies were purchased from Fisher Scientific and used without
purification. The concentration of the ammonium hydroxide
used in the chromatography experiments was 28−30%.
4.2. Synthesis of DMT (1). To an ice-cold solution of
tryptamine (0.60 g, 3.1 mmol) and glacial acetic acid (0.88 mL,
15 mmol, 5.0 equiv) in MeOH (48 mL) was added sodium
cyanoborohydride (0.40 g, 6.4 mmol, 2.1 equiv) followed by
37% formaldehydeaq (0.64 mL, 7.9 mmol, 2.6 equiv). The
reaction was stirred at room temperature for 5 h, at which time
the mixture was transferred equally to three separate vials.
Concentration under reduced pressure afforded an unpurified
solid, which was dissolved in either DCM, diethyl ether, or
CHCl3 (25 mL) and diluted with 1.0 M NaOHaq (75 mL). The
phases were separated and the aqueous phase was extracted
twice with solvent (25 mL). The organic extracts were
combined, dried over Na2SO4, filtered, and concentrated
under reduced pressure to yield a colorless oil. The unpurified
oil was dissolved in acetone (5 mL) and added dropwise to a
boiling solution of fumaric acid (0.059 g, 0.50 mmol, 0.50
equiv) in acetone (15 mL). A precipitate formed immediately.
The solution was allowed to cool to room temperature and
filtered. The white solid was dried under reduced pressure to
yield the pure compound as the fumarate salt (2:1 DMT/
fumaric acid) (DCM: 0.207 g, 0.084 mmol, 83%; CHCl3: 0.199
g, 0.081 mmol, 79%; diethyl ether: 0.215 g, 0.87 mmol, 86%).
TLC Rf (DMT free base) = 0.35 (9:1 DCM/MeOH 1%
NH4OHaq); mp 140−142 °C; 1H NMR (400 MHz, DMSO-
d6): δ 10.8 (br s, 1H), 7.5 (d, 1H, J = 7.9 Hz), 7.3 (d, 1H, J =
7.9 Hz), 7.1 (s, 1H), 7.0 (t, 1H, J = 7.9 Hz), 6.9 (t, 1H, J = 7.9
Hz), 6.5 (s, 1H), 2.9 (t, 2H, J = 8.0 Hz), 2.8 (t, 2H, J = 8.0 Hz),
2.4 (s, 6H) ppm; 13C NMR (100 MHz, CD3OD): δ 173.8,
138.2, 136.9, 128.1, 124.2, 122.7, 120.1, 119.0, 112.5, 110.0,
59.2, 43.4, 21.9 ppm; IR (diamond, ATR) ν ̅max: 3483, 3146,
3107, 3045, 2927, 2881, 1561, 1226, 749 cm−1. LC−MS (ES+)
calcd for C12H16N2
+, 188.13; found, 189.32 (MH+).
4.3. Synthesis of N-Chloromethyl-N,N-dimethyltrypt-
amine Chloride (10). The DMT free base [0.050 g, 0.26
mmol; see below for a procedure for preparing the free base
from the DMT/fumarate (2:1) salt] was dissolved in DCM (5
mL) to give a concentration of 10 mg/mL (0.05 M) The vial
was blanketed with N2 and stored in the dark. After 5 days, the
precipitate that had formed was filtered, rinsed with DCM and
dried under reduced pressure to yield 10 as an off-white solid
(0.027 g, 0.076 mmol, 19%). 1H NMR (400 MHz, DMSO-d6):
δ 11.1 (br s, 1H), 7.6 (d, 1H, J = 8.0 Hz), 7.4 (d, 1H, J = 8.0
Hz), 7.3 (s, 1H), 7.1 (t, 1H, J = 8.0 Hz), 7.0 (t, 1H, J = 8.0 Hz),
5.5 (s, 2H), 3.7 (t, 2H, J = 8.1 Hz), 3.3 (s, 6H) 3.2 (t, 2H, J =
8.1 Hz) ppm; 13C NMR (100 MHz, DMSO-d6): δ 136.2, 126.5,
123.7, 121.3, 118.6, 118.2, 111.7, 107.7, 68.1, 62.1, 48.9, 18.3
ppm; IR (diamond, ATR) ν̅max: 3142, 3047, 3017, 2999, 2923,
2863, 866, 755, 727 cm−1. LC−MS (ES+) calcd for
C13H18Cl2N2
+, 237.12; found, 237.22 (M+).
4.4. Conversion of DMT/Fumarate (2:1) to the Free
Base. DMT/fumarate (2:1) (0.20 g, 0.82 mmol) was basified
using 1.0 M NaOHaq (30 mL) and extracted twice with diethyl
ether (20 mL). The organic extracts were combined, dried over
Na2SO4, filtered, and concentrated under reduced pressure to
yield DMT free base (0.11 g, 0.58 mmol, 71%).
4.5. DMT Degradation in Pure Solvent. The free base of
DMT (as prepared above) was dissolved in either DCM or
CHCl3 to give a concentration of 10 mg/mL (0.05 M). The vial
was blanketed with N2 and stored in the dark. Aliquots were
taken at various time points (1 h, 1 day, 2 days, 3 days, and 4
days) and concentrated under reduced pressure. Care was taken
to ensure that the mixture was homogenous before aliquots
were taken. The unpurified samples were dissolved in 0.6 mL of
DMSO-d6 and
1H NMR spectra were obtained. The aliquot
taken after 4 days was also subjected to analysis by LC−MS to
confirm the formation of 10.
4.6. DMT Degradation under Biphasic Basic Work-Up
Conditions. The free base of DMT (as prepared above) was
dissolved in DCM to give a concentration of 10 mg/mL (0.05
M). To this solution was added an equal volume of 1.0 M
NaOHaq. The vial was blanketed with N2 and stored in the
dark. Aliquots were taken at 5 min, 15 min, 30 min, 1 h, and 1
day from the aqueous layer, neutralized with 2.0 M HClaq, and
subjected to analysis by SIM LC−MS using caffeine as an
internal standard. Aliquots from the organic layer were taken at
the same time points, concentrated under reduced pressure,
diluted with methanol, and subjected to analysis by SIM LC−
MS using caffeine as an the internal standard. Standard curves
were prepared by comparing SIM peak integrations for
increasing concentrations of purified DMT/fumarate (2:1) or
10 relative to a constant concentration of caffeine as an internal
standard.
4.7. DMT Degradation under Column Chromatog-
raphy Conditions. The free base of DMT (as prepared
above) was dissolved in 9:1 DCM/MeOH with 1% NH4OHaq
to give a concentration of 10 mg/mL (0.05 M). The vial was
blanketed with N2 and stored in the dark. Aliquots were taken
at 5 min, 15 min, 30 min, 1 h, and 1 day, and then concentrated
under reduced pressure. The unpurified samples were dissolved
in 0.6 mL of DMSO-d6, and
1H NMR spectra were obtained.
An aliquot taken after 1 day was also subjected to analysis by
LC−MS to confirm the formation of 10.
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E.; de la Fuente Revenga, M.; Friedlander, P.; Feilding, A.; Riba, J.
Ayahuasca: Pharmacology, neuroscience and therapeutic potential.
Brain Res. Bull. 2016, 126, 89−101.
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